December 16, 2020 -- Neurogene has completed $115 million in series B financing, which will be used to advance various aspects of the company's gene therapy programs and technology.
The funds will help advance the company's collection of gene therapy programs, support novel gene therapy design, invest in the company's technology platform, and expand Neurogene's adeno-associated virus (AAV) vector good manufacturing practice manufacturing capabilities. Neurogene's lead programs use AAV vector-based gene therapy technology to treat rare, neurological diseases.
The round of financing was led by EcoR1 Capital, with participation from existing and new investors.